PDT-induced inflammatory and host responses - PubMed (original) (raw)
doi: 10.1039/c0pp00308e. Epub 2011 Jan 24.
Affiliations
- PMID: 21258727
- DOI: 10.1039/c0pp00308e
PDT-induced inflammatory and host responses
Małgorzata Firczuk et al. Photochem Photobiol Sci. 2011 May.
Abstract
Photodynamic therapy (PDT) is used in the management of neoplastic and nonmalignant diseases. Its unique mechanisms of action include direct cytotoxic effects exerted towards tumor cells, destruction of tumor and peritumoral vasculature and induction of local acute inflammatory reaction. The latter develops in response to (1) damage to tumor and stromal cells that leads to the release of cell death-associated molecular patterns (CDAMs) or damage associated molecular patterns (DAMPs), (2) early vascular changes that include increased vascular permeability, vascular occlusion, and release of vasoactive and proinflammatory mediators, (3) activation of alternative pathway of complement leading to generation of potent chemotactic factors, and (4) induction of signaling cascades and transcription factors that trigger secretion of cytokines, matrix metalloproteinases, or adhesion molecules. The majority of studies indicate that induction of local inflammatory response contributes to the antitumor effects of PDT and facilitates development of systemic immunity. However, the degree of PDT-induced inflammation and its subsequent contribution to its antitumor efficacy depend on multiple parameters, such as chemical nature, concentration and subcellular localization of the photosensitizers, the spectral characteristics of the light source, light fluence and fluence rate, oxygenation level, and tumor type. Identification of detailed molecular mechanisms and development of therapeutic approaches modulating PDT-induced inflammation will be necessary to tailor this treatment to particular clinical conditions.
Similar articles
- Antitumor immunity promoted by vascular occluding therapy: lessons from vascular-targeted photodynamic therapy (VTP).
Preise D, Scherz A, Salomon Y. Preise D, et al. Photochem Photobiol Sci. 2011 May;10(5):681-8. doi: 10.1039/c0pp00315h. Epub 2011 Jan 24. Photochem Photobiol Sci. 2011. PMID: 21258718 Review. - Direct tumor damage mechanisms of photodynamic therapy.
Nowis D, Makowski M, Stokłosa T, Legat M, Issat T, Gołab J. Nowis D, et al. Acta Biochim Pol. 2005;52(2):339-52. Epub 2005 Jun 25. Acta Biochim Pol. 2005. PMID: 15990919 Review. - Photodynamic therapy: illuminating the road from cell death towards anti-tumour immunity.
Garg AD, Nowis D, Golab J, Agostinis P. Garg AD, et al. Apoptosis. 2010 Sep;15(9):1050-71. doi: 10.1007/s10495-010-0479-7. Apoptosis. 2010. PMID: 20221698 Review. - Correlation of subcellular and intratumoral photosensitizer localization with ultrastructural features after photodynamic therapy.
Peng Q, Moan J, Nesland JM. Peng Q, et al. Ultrastruct Pathol. 1996 Mar-Apr;20(2):109-129. doi: 10.3109/01913129609016306. Ultrastruct Pathol. 1996. PMID: 8882357 Review. - DAMPs and PDT-mediated photo-oxidative stress: exploring the unknown.
Garg AD, Krysko DV, Vandenabeele P, Agostinis P. Garg AD, et al. Photochem Photobiol Sci. 2011 May;10(5):670-80. doi: 10.1039/c0pp00294a. Epub 2011 Jan 24. Photochem Photobiol Sci. 2011. PMID: 21258717 Review.
Cited by
- Necroptosis as a consequence of photodynamic therapy in tumor cells.
de Souza ÁC, Mencalha AL, Fonseca ASD, de Paoli F. de Souza ÁC, et al. Lasers Med Sci. 2024 Nov 1;39(1):267. doi: 10.1007/s10103-024-04218-5. Lasers Med Sci. 2024. PMID: 39482559 Review. - Enhancing cancer immunotherapy with photodynamic therapy and nanoparticle: making tumor microenvironment hotter to make immunotherapeutic work better.
Thiruppathi J, Vijayan V, Park IK, Lee SE, Rhee JH. Thiruppathi J, et al. Front Immunol. 2024 Apr 5;15:1375767. doi: 10.3389/fimmu.2024.1375767. eCollection 2024. Front Immunol. 2024. PMID: 38646546 Free PMC article. Review. - Current Challenges and Opportunities of Photodynamic Therapy against Cancer.
Huis In 't Veld RV, Heuts J, Ma S, Cruz LJ, Ossendorp FA, Jager MJ. Huis In 't Veld RV, et al. Pharmaceutics. 2023 Jan 18;15(2):330. doi: 10.3390/pharmaceutics15020330. Pharmaceutics. 2023. PMID: 36839652 Free PMC article. Review. - Modified hollow mesoporous silica nanoparticles as immune adjuvant-nanocarriers for photodynamically enhanced cancer immunotherapy.
Li Q, Liu Q, Li H, Dong L, Zhou Y, Zhu J, Yang L, Tao J. Li Q, et al. Front Bioeng Biotechnol. 2022 Oct 11;10:1039154. doi: 10.3389/fbioe.2022.1039154. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 36304892 Free PMC article. - Effects of hypericin encapsulated on Pluronic F127 photodynamic therapy against triple negative breast cancer.
De Souza MVF, Shinobu-Mesquita CS, Meirelles LEF, Mari NL, César GB, Gonçalves RS, Caetano W, Damke E, Silva VR, Damke GM, Consolaro MEL. De Souza MVF, et al. Asian Pac J Cancer Prev. 2022 May 1;23(5):1741-1751. doi: 10.31557/APJCP.2022.23.5.1741. Asian Pac J Cancer Prev. 2022. PMID: 35633560 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources